Scientists also revealed that circular fragments of DNA called extrachromosomal DNA (ecDNA) is a significant source of drug ...

The accelerated approval of Trodelvy for patients with metastatic urothelial cancer has been voluntarily withdrawn.

A research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve ...

Bladder cancer is the second most common urologic cancer in men in the U.S., with high recurrence rates, especially in non-muscle-invasive cases. The FDA has accepted a new drug application for the ...

Patients with advanced bladder cancer that has spread to other parts of the body (metastasized) have responded well in a phase I clinical trial of an investigational drug, TYRA-300.

Oct 18 (Reuters) - Gilead Sciences (GILD.O), opens new tab said on Friday it was voluntarily withdrawing its drug, Trodelvy, for patients with a type of bladder cancer after it failed to meet the ...

Here’s a summary of what happened last month. Medscape Medical News, November 05, 2024 Gilead Withdraws Bladder Cancer Drug in US After Failed Trial Gilead Sciences said on Friday it was ...

Patients with advanced bladder cancer that had spread to other parts of the body (metastasized) have responded well in a phase I clinical trial of an investigational drug, TYRA-300. The drug ...

Gilead will no longer sell its combination drug Trodelvy to treat bladder cancer, announcing Friday it had agreed with the Food and Drug Administration to withdraw it following negative trial results.

Barcelona, Spain: Patients with advanced bladder cancer that had spread to other parts of the body (metastasised) have responded well in a phase I clinical trial of an investigational drug ...